✦ LIBER ✦

Infliximab and the bone in Crohn's disease

✍ Scribed by N. Franchimont; C. Reenaers; E. Louis

Book ID: 108604044
Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 47 KB
Volume: 21
Category: Article
ISSN: 0269-2813
DOI: 10.1111/j.1365-2036.2005.02434.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Infliximab and the bone in Crohn's disea

Infliximab and the bone in Crohn's disease

✍ R. Kunisaki; O. Chaki; T. Taguchi; T. Sugiyama; A. Sugita 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 48 KB

Infliximab dose intensification in Crohn

Infliximab dose intensification in Crohn's disease

✍ Miguel Regueiro; Benjamin Siemanowski; Kevin E. Kip; Scott Plevy 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 176 KB 👁 1 views

Background: Crohn's disease (CD) patients who lose response to infliximab may benefit from an increase in dose or decrease in interval between infusions. The aims of this study were to determine the proportion of CD patients who require dose intensification and factors associated with dose intensifi

Rapid improvement of bone metabolism aft

Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease

✍ N. Franchimont; V. Putzeys; J. Collette; S. Vermeire; P. Rutgeerts; M. De Vos; A 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB

Infliximab dependency in children with C

Infliximab dependency in children with Crohn’s disease

✍ D. DURICOVA; N. PEDERSEN; M. LENICEK; O. HRADSKY; J. BRONSKY; M. ADAMCOVA; M. EL 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 188 KB

Crohn's disease, infliximab and idiopath

Crohn's disease, infliximab and idiopathic thrombocytopenic purpura

✍ Lisbeth A. Selby; David Hess; Harohalli Shashidar; Willem J.S. de Villiers; Lisb 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 64 KB

Infliximab vs. Adalimumab for Crohn's di

Infliximab vs. Adalimumab for Crohn's disease

✍ P. Mulani; J. Chao 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 41 KB